Overview

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the safety and efficacy of Azacytidine in fludarabine-resistant chronic lymphocytic leukemia (CLL), Richter's transformation, and T-cell prolymphocytic leukemia (T-PLL).
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Azacitidine